Stress Echocardiography to Identify Chemotherapy Induced Cardiotoxicity in Cancer Patients With Heart Failure Risk

Inclusion Criteria: * Current or previous diagnosis of solid organ cancers (breast, non-small cell lung, rectal, renal, hepatic cancer, metastatic melanoma, sarcoma) or hematological disease (lymphoma, leukemia, multiple myeloma, monoclonal gammopathy of undetermined significance \[MGUS\]) * Age \>= 18 years at study enrollment * Plan to receive, or history of having received, chemotherapy (anthracycline, alkylating agent \[cyclophosphamide, ifosfamide\], and/or antimicrotubule agent \[docetaxel, paclitaxel\]) with or without specific targeted therapies; * Anti-HER2 targeted therapies (trastuzumab, pertuzumab) * Vascular endothelial growth factor (VEGF) inhibitors (bevacizumab, sunitinib, sorafenib, pazopanib, axitinib, vandetanib) * Immune checkpoint inhibitors (ipilimumab, nivolumab, pembrolizumab) * Plan to undergo conditioning chemotherapy for bone marrow transplantation (autologous/allogeneic) Exclusion Criteria: * Coronary artery disease * Significant (more than mild) valvular heart disease * Pre-existing heart failure * Pre-existing cardiomyopathy * Musculoskeletal or neurologic abnormality prohibiting low intensity exercise on a stationary bicycle * Severe pulmonary disease limiting ability to perform low intensity exercise on a stationary bicycle